Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
E For L Aim PCLBKK:EFORL-R 40 Cyclically Adjusted Price-to-FCF is 6.00 as of Sep. 03, 2026, which is at its 10-year median of 6.00. GuruFocus rates BKK:EFORL-R with a GF Score™ of 40/100 and a GF Value™ of ฿0.14 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 51 Medical Distribution companies, E For L Aim PCL ranks better than 86.27% on this metric.
The historical rank and industry rank for E For L Aim PCL's Cyclically Adjusted Price-to-FCF or its related term are showing as below:
BKK:EFORL-R'
s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 5.03 Med: 6 Max: 6.5
Current: 5.03
During the past years, E For L Aim PCL's highest Cyclically Adjusted Price-to-FCF was 6.50. The lowest was 5.03. And the median was 6.00.
BKK:EFORL-R's Cyclically Adjusted Price-to-FCF is ranked better than 86.27% of 51
companies
in the Medical Distribution industry
Industry Median: 21.5
vs BKK:EFORL-R: 5.03
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.
E For L Aim PCL's adjusted free cash flow per share data for the three months ended in Jun. 2026 was ฿-0.001. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is ฿0.02 for the trailing ten years ended in Jun. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
E For L Aim PCL (BKK:EFORL-R) Cyclically Adjusted Price-to-FCF Explanation
Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.
E For L Aim PCL Cyclically Adjusted Price-to-FCF Related Terms
E For L Aim PCL Cyclically Adjusted Price-to-FCF Historical Data
* Premium members only.
The historical data trend for E For L Aim PCL's Cyclically Adjusted Price-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
E For L Aim PCL Cyclically Adjusted Price-to-FCF Chart
BKK:EFORL-R vs MCK, COR, CAH: Cyclically Adjusted Price-to-FCF Comparison
For the Medical Distribution subindustry, E For L Aim PCL's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
E For L Aim PCL Cyclically Adjusted Price-to-FCF vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, E For L Aim PCL's Cyclically Adjusted Price-to-FCF distribution charts can be found below:
* The bar in red indicates where E For L Aim PCL's Cyclically Adjusted Price-to-FCF falls into.
E For L Aim PCL Cyclically Adjusted Price-to-FCF Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.
E For L Aim PCL's Cyclically Adjusted Price-to-FCF for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted Price-to-FCF of 6.00 mean?
E For L Aim PCL (BKK:EFORL-R) has a Cyclically Adjusted Price-to-FCF of 6.00 as of Sep. 03, 2026. Cyclically Adjusted Price-to-FCF Ratio is the ratio of share price to a company's inflation-adjusted FCF per share over a 10-year period. View historical data on E For L Aim PCL and its competitors. This is near median its historical median of 6.00. Over the past decade, E For L Aim PCL's Cyclically Adjusted Price-to-FCF has ranged from 5.03 to 6.50. According to the industry distribution chart, E For L Aim PCL ranks #7 out of 51 companies in the Medical Distribution industry, placing it in the top 13.7%.
Is E For L Aim PCL's Cyclically Adjusted Price-to-FCF too high?
E For L Aim PCL's current Cyclically Adjusted Price-to-FCF of 6.00 is near median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 5.03 to a high of 6.50. The Medical Distribution industry median Cyclically Adjusted Price-to-FCF is 21.50. E For L Aim PCL's value of 6.00 is 72.1% below this industry median. Based on the distribution chart, E For L Aim PCL ranks #7 out of 51 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, E For L Aim PCL has a GF Score™ of 40/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does E For L Aim PCL's Cyclically Adjusted Price-to-FCF compare to MCK and COR?
According to the Medical Distribution industry distribution chart, E For L Aim PCL ranks #7 out of 51 companies for Cyclically Adjusted Price-to-FCF. This places E For L Aim PCL in the top 14% of its industry — outperforming the majority of peers. The industry median Cyclically Adjusted Price-to-FCF is 21.50. E For L Aim PCL's value of 6.00 is 72.1% below this benchmark. Historically, E For L Aim PCL's own Cyclically Adjusted Price-to-FCF has ranged from 5.03 to 6.50 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 21.50, E For L Aim PCL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Price-to-FCF for a Medical Distribution company?
The median Cyclically Adjusted Price-to-FCF among Medical Distribution companies is 21.50, based on 51 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted Price-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted Price-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. E For L Aim PCL's current Cyclically Adjusted Price-to-FCF of 6.00 is 72.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Price-to-FCF mean?
A high Cyclically Adjusted Price-to-FCF can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted Price-to-FCF Ratio is the ratio of share price to a company's inflation-adjusted FCF per share over a 10-year period. View historical data on E For L Aim PCL and its competitors. For the Medical Distribution industry, the median Cyclically Adjusted Price-to-FCF is 21.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. E For L Aim PCL's current Cyclically Adjusted Price-to-FCF is 6.00, which is near median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is E For L Aim PCL stock overvalued right now?
Based on GuruFocus' analysis, E For L Aim PCL (BKK:EFORL-R) is currently considered Modestly Undervalued. The stock's GF Value™ is ฿0.14, compared to a current price of ฿0.12 — trading 14.3% below its estimated fair value. The current Cyclically Adjusted Price-to-FCF is 6.00, which is near median its 10-year median of 6.00 and 72.1% below the Medical Distribution industry median of 21.50. E For L Aim PCL's overall GF Score™ is 40/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Price-to-FCF calculated?
Cyclically Adjusted Price-to-FCF is calculated from a company's financial statements. For E For L Aim PCL (BKK:EFORL-R), the current Cyclically Adjusted Price-to-FCF is 6.00 as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is E For L Aim PCL (BKK:EFORL-R) Overvalued in 2026?
Based on GuruFocus' analysis, E For L Aim PCL stock appears to be undervalued.
The current stock price of ฿0.12 is trading 14.3% below its estimated GF Value™ of ฿0.14.
GuruFocus considers E For L Aim PCL to be Modestly Undervalued.
Key valuation signals for BKK:EFORL-R:
Cyclically Adjusted Price-to-FCF: 6.00 (near median its 10-year median of 6.00)
GF Value™: ฿0.14 vs. price of ฿0.12 (14.3% below fair value)
Industry Position: 72.1% below the Medical Distribution median (#7 of 51)
No single metric tells the full story. See the BKK:EFORL-R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
E For L Aim PCL is engaged in the distribution of medical devices and equipment. The company and subsidiary have distributor agreements for medical devices and equipment with foreign companies. Its products include Patient Monitor System, Central Monitors System, Defibrillator, Automated External Defibrillator (AED), Electrocardiographs, Electroencephalogram (EEG), PSG System (Sleep Labs), and Accessories and Consumables. The group is principally engaged in one operating segment which is the distribution of medical device and equipment and providing service of medical equipment. Their operations are carried out in Thailand.
40GF Score
Get the complete analysis for BKK:EFORL-R
Cyclically Adjusted Price-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:EFORL-R has been successfully added to your 
